サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1360304

ライム病診断市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年から2031年

Lyme Disease Diagnostics Market (Diagnostic Test: Serological Test, Polymerase Chain Reaction Test, and Others; and Sample: Blood, Cerebrospinal Fluid, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ライム病診断市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年から2031年
出版日: 2023年08月08日
発行: Transparency Market Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ライム病診断市場- レポートの範囲

世界のライム病診断市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界のライム病診断の収益を提供します。 2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間の市場を分析します。レポートは、2023年から2031年までの世界のライム病診断市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、ライム病診断市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 15億米ドル
2031年の市場価値 21億米ドル
CAGR 3.8%

このレポートは、世界のライム病診断市場の競合情勢を詳しく掘り下げています。世界のライム病診断市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のライム病診断市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • ライム病の診断検査における革新
  • ライム病の発生率と有病率
  • 地域/世界ごとの規制シナリオ
  • COVID-19パンデミックによる業界への影響（バリューチェーンと短期・中期・長期的な影響）

第6章 世界市場の分析と予測：診断テスト別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：診断テスト別、2017-2031
    • 血清学的検査
      • ELISA
      • ウエスタンブロット
    • ポリメラーゼ連鎖反応（PCR）検査
    • その他
  • 市場魅力分析：診断テスト別

第7章 世界市場の分析と予測：サンプル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：サンプル別、2017-2031
    • 血
    • 脳脊髄液（CSF）
    • その他
  • 市場魅力分析：サンプル別

第8章 世界市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：エンドユーザー別、2017-2031
    • 病院
    • 診断研究所
    • その他
  • 市場魅力分析：エンドユーザー別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東およびアフリカ市場の分析と予測

第15章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • LabCorp
    • Quest Diagnostics
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • DiaSorin SpA
    • T2 Biosystems, Inc.
    • F. Hoffmann-La Roche AG
    • Meridian Bioscience, Inc.
    • Quidel Corporation
図表

List of Tables

  • Table 01: Global Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017-2031
  • Table 02: Global Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Serological Test, 2017-2032
  • Table 03: Global Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Sample, 2017-2031
  • Table 04: Global Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017-2032
  • Table 05: Global Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017-2031
  • Table 07: North America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Serological Test, 2017-2031
  • Table 08: North America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Sample, 2017-2032
  • Table 09: North America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 10: North America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 11: Europe Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017-2031
  • Table 12: Europe Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Serological Test, 2017-2031
  • Table 13: Europe Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Sample, 2017-2031
  • Table 14: Europe Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 15: Europe Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 16: Asia Pacific Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017-2031
  • Table 17: Asia Pacific Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Serological Test, 2017-2031
  • Table 18: Asia Pacific Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Sample, 2017-2031
  • Table 19: Asia Pacific Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 20: Asia Pacific Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 21: Latin America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017-2031
  • Table 22: Latin America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Serological Test, 2017-2031
  • Table 23: Latin America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Sample, 2017-2031
  • Table 24: Latin America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 25: Latin America Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 26: Middle East & Africa Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic test, 2017-2031
  • Table 27: Middle East & Africa Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Serological Test, 2017-2031
  • Table 28: Middle East & Africa Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Sample, 2017-2031
  • Table 29: Middle East & Africa Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 30: Middle East & Africa Lyme Disease Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2031

List of Figures

  • Figure 01: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Lyme Disease Diagnostics Market Value Share, by Diagnostic Test, 2022
  • Figure 03: Global Lyme Disease Diagnostics Market Value Share, by Sample, 2022
  • Figure 04: Global Lyme Disease Diagnostics Market Value Share, by End-user, 2022
  • Figure 05: Global Lyme Disease Diagnostics Market Value Share, Analysis, by Diagnostic Test, 2022 and 2031
  • Figure 06: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Serological Test, 2017-2031
  • Figure 07: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Polymerase Chain Reaction (PCR) Test, 2017-2031
  • Figure 08: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 09: Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023-2031
  • Figure 10: Global Lyme Disease Diagnostics Market Value Share, Analysis, by Sample, 2022 and 2031
  • Figure 11: Global Lyme Disease Diagnostics Market Revenue (US$ Mn) by Blood, 2017-2031
  • Figure 12: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Cerebrospinal Fluid (CSF), 2017-2031
  • Figure 13: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 14: Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2023-2031
  • Figure 15: Global Lyme Disease Diagnostics Market Value Share, Analysis, by End-user, 2022 and 2031
  • Figure 16: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Hospitals, 2017-2031
  • Figure 17: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Diagnostic Laboratories, 2017-2031
  • Figure 18: Global Lyme Disease Diagnostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 19: Global Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 20: Global Lyme Disease Diagnostics Market Value Share, Analysis, by Region, 2022 and 2031
  • Figure 21: Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 22: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: North America Lyme Disease Diagnostics Market Value Share, Analysis, by Country, 2022 and 2031
  • Figure 24: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 25: North America Lyme Disease Diagnostics Market Value Share, Analysis, by Diagnostic Test, 2022 and 2031
  • Figure 26: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023-2031
  • Figure 27: North America Lyme Disease Diagnostics Market Value Share, Analysis, by Sample, 2022 and 2031
  • Figure 28: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2023-2031
  • Figure 29: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 30: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 31: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: Europe Lyme Disease Diagnostics Market Value Share, Analysis, by Country, 2022 and 2031
  • Figure 33: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 34: Europe Lyme Disease Diagnostics Market Value Share, Analysis, by Diagnostic Test, 2022 and 2031
  • Figure 35: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023-2031
  • Figure 36: Europe Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2022 and 2031
  • Figure 37: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2023-2031
  • Figure 38: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 39: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 40: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 41: Asia Pacific Lyme Disease Diagnostics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 42: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 43: Asia Pacific Lyme Disease Diagnostics Market Value Share, Analysis, by Diagnostic Test, 2022 and 2031
  • Figure 44: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023-2031
  • Figure 45: Asia Pacific Lyme Disease Diagnostics Market Value Share, Analysis, by Sample, 2022 and 2031
  • Figure 46: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2023-2031
  • Figure 47: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 48: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 49: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Latin America Lyme Disease Diagnostics Market Value Share, Analysis, by Country, 2022 and 2031
  • Figure 51: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 52: Latin America Lyme Disease Diagnostics Market Value Share, Analysis, by Diagnostic Test, 2022 and 2031
  • Figure 53: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023-2031
  • Figure 54: Latin America Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2022 and 2031
  • Figure 55: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2023-2031
  • Figure 56: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 57: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 58: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn), 2017-2031
  • Figure 59: Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 60: Middle East & Africa Lyme Disease Diagnostics Market Attractiveness, by Country, 2023-2031
  • Figure 61: Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test, 2022 and 2031
  • Figure 62: Middle East & Africa Lyme Disease Diagnostics Market Attractiveness, by Diagnostic Test, 2023-2031
  • Figure 63: Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2022 and 2031
  • Figure 64: Middle East & Africa Lyme Disease Diagnostics Market Attractiveness, by Sample, 2023-2031
  • Figure 65: Middle East & Africa Lyme Disease Diagnostics Market Attractiveness, by End-user, 2023-2032
  • Figure 66: Middle East & Africa Lyme Disease Diagnostics Market Attractiveness, by End-user, 2023-2031
  • Figure 67: Company Share Analysis Lyme Disease Diagnostics, 2022
目次
Product Code: TMRGL1658

Lyme Disease Diagnostics Market - Scope of Report

TMR's report on the global lyme disease diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lyme disease diagnostics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lyme disease diagnostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lyme disease diagnostics market.

Market Snapshot
Market Value in 2023US$ 1.5 Bn
Market Value in 2031US$ 2.1 Bn
CAGR3.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lyme disease diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lyme disease diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lyme disease diagnostics market.

The report delves into the competitive landscape of the global lyme disease diagnostics market. Key players operating in the global lyme disease diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lyme disease diagnostics market profiled in this report.

Key Questions Answered in Global Lyme Disease Diagnostics Market Report:

  • What is the sales/revenue generated by lyme disease diagnostics across all regions during the forecast period?
  • What are the opportunities in the global lyme disease diagnostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Lyme Disease Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global lyme disease diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lyme disease diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lyme disease diagnostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Lyme Disease Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Lyme Disease Diagnostics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projection (US$ Mn)

5. Key Insights

  • 5.1. Innovations in Diagnostic Testing for Lyme disease
  • 5.2. Incidence and Prevalence of Lyme Disease
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)

6. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Diagnostic Test

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 6.3.1. Serological Test
      • 6.3.1.1. ELISA
      • 6.3.1.2. Western Blot
    • 6.3.2. Polymerase Chain Reaction (PCR) test
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Diagnostic Test

7. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Sample

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Sample, 2017-2031
    • 7.3.1. Blood
    • 7.3.2. Cerebrospinal Fluid (CSF)
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Sample

8. Global Lyme Disease Diagnostics Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Hospitals
    • 8.3.2. Diagnostic Laboratories
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Lyme Disease Diagnostics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 10.2.1. Serological Test
      • 10.2.1.1. ELISA
      • 10.2.1.2. Western Blot
    • 10.2.2. Polymerase Chain Reaction (PCR) test
    • 10.2.3. Others
  • 10.3. Market Value Forecast, by Sample, 2017-2031
    • 10.3.1. Blood
    • 10.3.2. Cerebrospinal Fluid (CSF)
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Hospitals
    • 10.4.2. Diagnostic Laboratories
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Diagnostic Test
    • 10.6.2. By Sample
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Lyme Disease Diagnostics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 11.2.1. Serological Test
      • 11.2.1.1. ELISA
      • 11.2.1.2. Western Blot
    • 11.2.2. Polymerase Chain Reaction (PCR) test
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Sample, 2017-2031
    • 11.3.1. Blood
    • 11.3.2. Cerebrospinal Fluid (CSF)
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Hospitals
    • 11.4.2. Diagnostic Laboratories
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Diagnostic Test
    • 11.6.2. By Sample
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Lyme Disease Diagnostics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 12.2.1. Serological Test
      • 12.2.1.1. ELISA
      • 12.2.1.2. Western Blot
    • 12.2.2. Polymerase Chain Reaction (PCR) test
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Sample, 2017-2031
    • 12.3.1. Blood
    • 12.3.2. Cerebrospinal Fluid (CSF)
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Hospitals
    • 12.4.2. Diagnostic Laboratories
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Diagnostic Test
    • 12.6.2. By Sample
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Lyme Disease Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 13.2.1. Serological Test
      • 13.2.1.1. ELISA
      • 13.2.1.2. Western Blot
    • 13.2.2. Polymerase Chain Reaction (PCR) test
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Sample, 2017-2031
    • 13.3.1. Blood
    • 13.3.2. Cerebrospinal Fluid (CSF)
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Hospitals
    • 13.4.2. Diagnostic Laboratories
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Diagnostic Test
    • 13.6.2. By Sample
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Lyme Disease Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 14.2.1. Serological Test
      • 14.2.1.1. ELISA
      • 14.2.1.2. Western Blot
    • 14.2.2. Polymerase Chain Reaction (PCR) test
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Sample, 2017-2031
    • 14.3.1. Blood
    • 14.3.2. Cerebrospinal Fluid (CSF)
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Hospitals
    • 14.4.2. Diagnostic Laboratories
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Diagnostic Test
    • 14.6.2. By Sample
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. LabCorp
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Quest Diagnostics
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Abbott Laboratories
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Bio-Rad Laboratories, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. bioMerieux SA
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. DiaSorin S.p.A.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. T2 Biosystems, Inc.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. F. Hoffmann-La Roche AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Meridian Bioscience, Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Quidel Corporation
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview